Enhanced risk of thrombosis in aged insulin-treated diabetic rats exposed to non-severe recurrent hypoglycemia
Related Experiment Video
Updated: Jan 8, 2026

Retinal Pathophysiological Evaluation in a Rat Model
Published on: May 6, 2022
Ashish K Rehni1,2, Sunjoo Cho1,2, Miguel A Perez-Pinzon1,2,3
1Peritz Scheinberg Cerebral Vascular Disease Research Laboratories, 1600 NW 10th Ave, Miami, 33136, FL, USA.
Background:
Antidiabetic treatment is linked with an increased risk of hypoglycemia. Several clinical studies have demonstrated that hypoglycemia exposure elevates the risk of cardiovascular diseases in diabetic patients. Our previous research has shown that non-severe recurrent hypoglycemia (RH) exposure increases the risk of thrombosis in young insulin-treated diabetic (ITD) rats. Given that a substantial subset of diabetes patients who experience cardiovascular complications are elderly and the effect of non-severe RH on thrombosis risk in aged subjects remains unknown, we tested the hypothesis that prior RH exposure enhances thrombosis in aged ITD rats.
Methods:
Aged, insulin-treated streptozotocin-diabetic Wistar rats of both sexes were randomly assigned to either the recurrent hyperinsulinemic euglycemia control or the recurrent hyperinsulinemic hypoglycemia group. The risk of thrombosis was quantified using an in vivo model.
Results:
RH increases the risk of thrombosis in male ITD rats 7 days after exposure. A twice-weekly hypoglycemia exposure for 6 weeks also elevated the risk of thrombosis in male rats. Similar exposures to RH also increased the risk of thrombosis in aged female rats.
Conclusions:
Exposure to non-severe RH increases the risk of thrombosis in aged ITD rats of both sexes. Nonetheless, it remains uncertain whether aging influences the characteristics of thrombosis observed in RH-exposed young ITD rats as well as its clinical consequences, highlighting the need for further research.
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Hypoglycemia and Glucagon
Oral Hypoglycemic Agents: Glinides
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational

